Cogent Biosciences (NASDAQ:COGT) Stock

COGENT BIOSCIENCES INC

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

News

Redwire Completes Integration of Hammerhead Spacecraft for ESA Tech Demo Mission, Marks Second Platform Milestone at Belgium Facility This Summer

To enhance the quality of life for its residents, Tatweer Misr, one of Egypt's leading real estate developers, has selected Otis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>), the world's leading elevator and escalator manufacturing, installation and service company, to supply and install smart vertical mobility solutions across its urban communities. Tatweer Misr's current engagement with Otis represents six projects and 1,250 elevators over six years.
&nbsp;
Since its establishment in 2014, Tatweer Misr has been at the forefront of real estate development in Egypt, continuously setting new benchmarks in urban development. The company is known for developing sustainable and smart urban communities. Through this collaboration, Tatweer Misr will integrate Otis's Gen2&#xAE; elevator systems, which offer energy efficiency, superior ride quality, and space-saving design, into Tatweer Misr's portfolio of six iconic projects that have established the company's footprint across Egypt's most strategic locations. These include the award-winning IL Monte Galala on the Red Sea; North Coast landmarks Fouka Bay, D-Bay, and Salt, each redefining coastal living; Bloomfields, a mixed-use, first-home community in Mostakbal City, East Cairo; Rivers, an upscale residential development in West Cairo, each designed to redefine modern, sustainable living.

OTIS

Otis Lands Deal to Install 1,250 Smart Elevators in Egypt's Top Urban Projects

PARA

Paramount Global Says Nickelodeon Added Spin Master's Unicorn Academy and Vida the Vet to July Lineup, Marking US Linear Debuts on Nickelodeon and Nick Jr.

EVGN

Evogene Completes Sale Of Lavie Bio Assets And MicroBoost AI Platform To ICL Group

Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>, <a href="https://www.globenewswire.com/Tracker?data=YIAvPI1Tp5RUL4j4EHFRaR_pm2cv7wJnKUs8dK9QHLFgGor0QOleG8-0VVeCjFTSYqs680G5KO0neTPfeAtnlg==">www.mrcy.com</a>))), a technology company that delivers mission-critical processing to the edge, today announced it received two new production awards in June totaling $36.9 million for ground-based radar programs that leverage its Common Processing Architecture and cybersecurity software from recently acquired Star Lab.

Government

Regulations

MRCY

Mercury Systems Wins $36.9M in Defense Contracts for Ground-Based Radar Tech

Keybanc analyst Sophie Karp upgrades SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Underweight to Sector Weight.

Upgrades

Analyst Ratings

SEDG

Keybanc Upgrades SolarEdge Technologies to Sector Weight

EPRX

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled RESOLVE Trial for Eosinophilic Esophagitis, Targeting Pivotal Study Readiness by Q3 2026

CRVO

CervoMed To Present Results From RewinD-LB Phase 2b Study Of Neflamapimod In Dementia With Lewy Bodies, At AAIC 2025

Biotech

Events

General

CervoMed To Present At Alzheimer's Association International Congress 2025 On July 27

<a href="https://www.globenewswire.com/Tracker?data=Sjm7HxugM0aKuCdtig1s0NCVhX9IUz-W8Mp8zVyUhHXfQqg2WbsApG6GwJU8XSA3lZstKPsqrfZBYjvWSvGs2veBvziXAsBoPL84_T7GNdw=">Plymouth Industrial REIT</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the second quarter of 2025. The Company also announced details for its second quarter earnings conference call and webcast to be held on August 7, 2025.
Leasing Activity Leases commencing during the second quarter ended June 30, 2025, which have terms of at least six months, totaled an aggregate of 1,453,757 square feet. These leases included:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Leases Commenced</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Q2</td>
<td>Renewal</td>
<td>1,159,623</td>
<td>79.8%</td>
<td>$</td>
<td>5.00</td>
<td>$</td>
<td>5.45</td>
<td>9.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>294,134</td>
<td>20.2%</td>
<td>$</td>
<td>4.92</td>
<td>$</td>
<td>5.61</td>
<td>14.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>1,453,757</td>
<td>100%</td>
<td>$</td>
<td>4.98</td>
<td>$</td>
<td>5.48</td>
<td>10.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
An additional 239,500 square feet has been leased on a short-term basis with auto-renewals and landlord kick-out options.
Total executed leases commencing during 2025, which had terms of at least six months, totaled an aggregate of 5,811,172 square feet. These leases, which represent 67.5% of total 2025 expirations, include:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>2025 Commencements</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent&nbsp;</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Renewal</td>
<td>4,095,835</td>
<td>70.5%</td>
<td>$</td>
<td>4.47</td>
<td>$</td>
<td>5.13</td>
<td>14.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>1,715,337</td>
<td>29.5%</td>
<td>$</td>
<td>4.27</td>
<td>$</td>
<td>4.64</td>
<td>8.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>5,811,172</td>
<td>100%</td>
<td>$</td>
<td>4.41</td>
<td>$</td>
<td>4.98</td>
<td>13.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Excluding the effect of the St. Louis Lease (as defined below), which commenced in the first quarter, rental rates under these leases would have reflected a 15.8% increase with new leases reflecting a 19.9% increase on a cash basis. The Company executed a two-year lease at its 769,500-square-foot Class A industrial building in the Metro East submarket of St. Louis, Missouri that commenced on January 15, 2025 (the "St. Louis Lease"). The lease is for 600,000 square feet during the first year and 450,000 square feet during the second year with a major international logistics service provider. This deal was done on an "as is" basis with no abatements making it attractive from a net lease rate perspective. While we continue to actively market the balance of the building, the existing tenant has leased the remaining 169,500 square feet on a rolling 90-day basis with landlord kick-out rights.
Total executed leases commencing in 2026, which have terms of at least six months, total an aggregate of 1,052,775 square feet, representing 13.7% of total 2026 expirations.
Same store occupancy at June 30, 2025, was 95.0%, while total portfolio occupancy at June 30, 2025, was 94.6%. Total portfolio occupancy changes from last quarter include:
<ul>
<li>50-basis-point net positive impact from leasing in St. Louis;</li>
<li>40-basis-point net positive impact from leasing in Cleveland;</li>
<li>40-basis-point net positive impact from leasing in Cincinnati;</li>
<li>Net 30-basis-point positive impact from acquisitions activity in the quarter; and</li>
<li>Net negative 130 basis-point impact from known leasing roll-over in Memphis (for which replacement interest has been high). &nbsp;</li>
</ul>
Acquisition Activity During the second quarter of 2025, Plymouth closed on the acquisition of 22 industrial buildings totaling 2.05 million square feet for a total of $204.7 million. Together, these properties are 97.1% leased and feature a weighted average remaining lease term of 2.6 years. The second quarter activity comprises the following:
<ul>
<li>100,420 square foot industrial building in southwest Atlanta, Georgia for $11.7 million at an expected initial net operating income ("NOI") yield of 6.95%; and</li>
<li>1.95 million square foot industrial portfolio encompassing 21 buildings located across Columbus, Cincinnati, and Cleveland for $193.0 million.</li>
</ul>
The Company used its existing unsecured line of credit to fund the abovementioned acquisitions. As of July 8, 2025, there is approximately $285.8 million of capacity on the line of credit.
Capital Markets Activity Under the Company's previously announced share repurchase program, through June 30, 2025, the Company has acquired and settled 805,394 shares of common stock at an average price per share of approximately $16.26.

PLYM

Plymouth Industrial Leases Nearly 5.8M Sq. Ft. in 2025, Rents Rise 13% on Renewals

<ul>
<li>More Than Doubles H2O America's Connections in Texas and Increases Exposure to High Growth Houston Region</li>
<li>Drives Scale, Increases Financial and Operational Diversification, and Enhances Value and Reliability for Customers, Communities, and All Stakeholders</li>
<li>Transaction Expected to be Accretive to Long-Term EPS Growth Rate; Texas Projected to Become Second Largest Utility Operation of H2O America by 20281</li>
<li>Company to Host Investor Webcast Today at 5:30 a.m. PT / 7:30 a.m. CT / 8:30 a.m. ET; Files Investor Presentation Highlighting Benefits of Proposed Combination</li>
</ul>

H2O America Acquires Quadvest In $540M Deal, More Than Doubling Texas Connections

Keybanc analyst Sophie Karp upgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Underweight to Sector Weight.

Keybanc Upgrades Sunrun to Sector Weight

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54286814&amp;newsitemid=20250708428715&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=603300247059cb367a81bfc1bb8c81dc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT, both in-person in San Francisco, California and virtually. Speakers will discuss the current burden of post-bariatric hypoglycemia (PBH) and background on avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation. Speakers will also review new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in post-bariatric hypoglycemia, which will be presented during ENDO 2025. These data include composite rates of Level 2 and 3 hypoglycemic events in both trials as well as new pharmacokinetic (PK) and pharmacodynamic (PD) data demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period.
Amylyx' management team will be joined by the following experts at the event:
<ul>
<li>Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY clinical trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Clinical Associate Professor of Medicine at Stanford University School of Medicine</li>
<li>Helen Lawler, MD, Investigator on the LUCIDITY Clinical Trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Associate Professor of Medicine in Endocrinology at University of Colorado at Denver School of Medicine</li>
<li>Colleen Craig, MD, Co-lead Investigator of Proof-of-Concept and First-in-Human Studies of Avexitide in PBH, led the avexitide development program during the Phase 2 PREVENT Clinical Trial, and Scientific Advisor and Consultant for Amylyx</li>
</ul>

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event

ADAG

Adagene Partners With ConjugateBio To Advance Bispecific Antibody Drug Conjugates Using Proprietary Antibody

PROK

ProKidney Reports Reports Statistically And Clinically Significant And Clinically Meaningful Results From Group 1 Modified Intent-To-Treat Population Of Phase 2 REGEN-007 Trial In Patients With CKD And Diabetes

<a href="https://www.globenewswire.com/Tracker?data=HPt9334Sk6sl9CV8M8CI3b_Pylq0SyAs_fh_RNpGc6aSmCQP_HnbSKuFUoQo_nUxWPw0D4zc-844HYk1PlFyQOW45NPrBZD8MjDHX7u7RCw=">Upstream Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the first patient has been dosed in the Company's Phase 2 clinical trial evaluating verekitug in patients with COPD, broadening the global development program for verekitug into a third indication.
Verekitug is a novel antibody antagonist of the Thymic Stromal Lymphopoietin (TSLP) receptor, a key driver of the inflammatory response in allergic and inflammatory diseases such as asthma, where agents targeting TSLP have demonstrated clinical benefits.
VENTURE (<a href="https://www.globenewswire.com/Tracker?data=5eGs73-MT3S5voM1JghBbOl0Q7PGWIvRYDYBbb1VCdRJWAWp3TtNiJKjlvq05oMFP5Sm2-tYnXrj_V1EdVwUotlNyJeuXpUUWj2M4fovkAHLaiNxozrMp7PD5W7yK9cN">NCT06981078</a>) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of verekitug in approximately 670 adults with moderate-to-severe COPD. Participants will be randomized to receive verekitug at doses of 100 mg once every 12 weeks, 400 mg once every 24 weeks, or placebo, over treatment periods of between 60 weeks and up to 108 weeks.
The primary endpoint of the study is the annualized rate of moderate or severe COPD exacerbations. Secondary endpoints include changes in participants' day-to-day symptoms as well as measures of lung function, such as forced expiratory volume in one second (FEV₁). Upstream Bio has designed this trial using endpoints that, pending interactions with regulatory authorities, could produce data to support submissions for product approval. The trial is enrolling patients regardless of blood eosinophil count, with the primary analysis focusing on those with elevated eosinophils at screening. Patients without elevated eosinophils at screening will be included to facilitate exploratory analyses of verekitug's efficacy in this population.
This COPD trial is part of the broader development program for verekitug that includes separate ongoing Phase 2 studies in CRSwNP and severe asthma. Upstream Bio completed enrollment in the Phase 2 trials in CRSwNP in January 2025 and in severe asthma in June 2025 and expects top-line data readouts in the third quarter of 2025 and the first quarter of 2026, respectively.

Upstream Bio Doses First COPD Patient in Phase 2 Trial for Anti-Inflammatory Drug Verekitug

Cryptourrencies are drifting upwards on Tuesday morning as markets expect further tariff-related news from the White House.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$108,823.13</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,563.84</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$151.17</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.29</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1697&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001184&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transcation increased by 95.4% and 312.2%, respectively. Daily active addresses are up by 14.3% and 0.08%, respectively.</li>
<li>Coinglass data shows 74,847 traders were liquidated in the past 24 hours for $162.83 million.</li>
<li>SoSoValue data shows net inflows of $216.6 million into spot Bitcoin ETFs on Monday. Spot Ethereum ETFs saw net inflows of $62.1 million.</li>
</ul>
Trader Notes: Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1942514777508438312">noted</a> Bitcoin has been stuck in a tight range for nearly two months. 
While short-term volatility remains choppy, he believes a breakout to new all-time highs could still materialize in July. 
The safer move is to wait, he said, though skilled traders are already positioned for the upside.
Daan Crypto Trades pointed out BTC's sluggish start to both the month and quarter is typical behavior, with price action bouncing between the Weekly and Monthly/Quarterly opens. 
He expects Bitcoin to remain in this consolidation range for another day or two. Despite geopolitical headline risks like tariff shocks, he said, "the market seems relatively unaffected."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Choppy start of the month &amp; quarter as we usually see. Currently stuck between the Weekly Open and the Monthly/Quarterly Open. Good chance we stick around this area for a day or two more before finally choosing a direction. Still some headline risk here and there with the… <a href="https://t.co/3TgMDWQ8FG">pic.twitter.com/3TgMDWQ8FG</a>
&mdash; Daan Crypto Trades (@DaanCrypto) <a href="https://twitter.com/DaanCrypto/status/1942486315263483955?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ted Labs co-founder Niels <a href="https://x.com/Web3Niels/status/1942513115339317755">sees</a> XRP as a potential early altseason signal. 
The coin is close to breaking out of a 7-month downtrend, and with RSI already breaking out, a weekly close above $2.40 could ignite a broader altcoin surge. 
He emphasized that historically, XRP breakouts have often preceded full-blown altseasons.
CryptoBatman observed Ethereum forming a megaphone pattern, signaling an upcoming breakout attempt. 
The next major resistance levels to watch are $3,500 and $4,200. A clean break above these could trigger a wider altcoin rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> is gearing up for another run with this megaphone pattern shaping up. The first hurdle is the resistance at $3500, then the major resistance at $4,200. Altcoins will explode right after. Buckle up. <a href="https://t.co/0I3kPTPYQW">pic.twitter.com/0I3kPTPYQW</a>
&mdash; BATMAN &#x26a1; (@CryptosBatman) <a href="https://twitter.com/CryptosBatman/status/1942512056420425981?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1942509254243729728">highlighted </a>Dogecoin's position inside an ascending broadening wedge on the weekly chart. DOGE is also contending with a parallel descending resistance trendline. A breakout here could indicate rising volatility and a possible strong upside continuation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46272572/scottie-pippen-is-watching-bitcoin-xrp-dogecoin-and-what-else">Scottie Pippen Is Watching Bitcoin, XRP, Dogecoin&#8230;And What Else?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Steady As Tariff Letters Shake Up Markets

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $5 price target.

Price Target

Rosenblatt Maintains Buy on Canaan, Maintains $5 Price Target

BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/BLK/earnings">opening bell on Tuesday, July 15</a>.
Analysts expect the New York-based company to report quarterly earnings at $10.60 per share, up from $10.36 per share in the year-ago period. BlackRock projects to report quarterly revenue of $5.41 billion, compared to $4.80 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 7, BlackRock announced plans to acquire ElmTree Funds.
BlackRock shares fell 0.6% to close at $1,075.97 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/blk/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Michael Brown maintained an Overweight rating and raised the price target from $1,105 to $1,180 on July 3, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Mike Cyprys maintained an Overweight rating and boosted the price target from $1,111 to $1,164 on July 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Goldman Sachs analyst Alexander Blostein maintained a Buy rating and boosted the price target from $994 to $1,115 on June 27, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Argus Research analyst Stephen Biggar maintained a Buy rating and raised the price target from $1,028 to $1,090 on June 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Brennan Hawken maintained a Neutral rating and cut the price target from $1,010 to $980 on April 16, 2025. This analyst has an accuracy rate of 73%</li>
</ul>
Considering buying BLK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/blk/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-1024x594.png" alt="" class="wp-image-975869" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46271576/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-8">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp BlackRock Expectations Ahead Of Q2 Earnings

HC Wainwright &amp; Co. analyst Scott Buck maintains BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) with a Buy and raises the price target from $20 to $28.

BlackSky Technology Inc. Class A Common Stock

BKSY

HC Wainwright & Co. Maintains Buy on BlackSky Technology, Raises Price Target to $28

Health Care

Press Releases

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Cogent Biosciences Reports First Quarter 2025 Financial Results

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Financing

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Comments

Cogent Biosciences

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL